42 research outputs found
Enfermedad Meningocócica en España. Análisis de la temporada 2016-2017
[ES] La enfermedad meningocócica es de declaración obligatoria en España. Los casos se notifican
de manera individualizada con periodicidad semanal, incluyendo información epidemiológica y
microbiológica a través de la Red Nacional de Vigilancia Epidemiológica (RENAVE). La presentación
de esta enfermedad en la población española ha sufrido cambios muy importantes. El uso de la
vacuna frente al serogrupo C ha causado un gran descenso de la incidencia por este serogrupo.
Además en la última década también han disminuido los casos por serogrupo B. En la temporada
2016-2017 se notificaron 321 casos, de los que se confirmaron 270 y la incidencia fue de 0,58 por
100.000 habitantes. Se presenta el análisis de los resultados generales de la vigilancia epidemiológica
de la enfermedad meningocócica para la temporada 2016-2017 en España y su comparación con las
previas.[EN] Meningococcal disease is notifiable in Spain. The cases were notified individually on a weekly
basis, including epidemiological and microbiological information through the National Network of
Epidemiological Surveillance (RENAVE). The incidence of this disease in the Spanish population has
undergone very important changes. Vaccination against serogroup C has caused a large decrease in
the incidence of this serogroup. In addition, in the last decade cases caused by serogroup B have
also decreased. In the 2016-2017 season, 321 cases were notified, of which 270 were confirmed
and the incidence was 0.58 per 100,000 inhabitants. We analyzed the results of the epidemiological
surveillance of meningococcal disease for the 2016-2017 season in Spain and its comparison with the
previous ones.N
Looking for a Better Characterization of Triple-Negative Breast Cancer by Means of Circulating Tumor Cells
Traditionally, studies to address the characterization of mechanisms promoting tumor aggressiveness and progression have been focused only on primary tumor analyses, which could provide relevant information but have limitations to really characterize the more aggressive tumor population. To overcome these limitations, circulating tumor cells (CTCs) represent a noninvasive and valuable tool for real-time profiling of disseminated tumor cells. Therefore, the aim of the present study was to explore the value of CTC enumeration and characterization to identify markers associated with the outcome and the aggressiveness of triple-negative breast cancer (TNBC). For that aim, the CTC population from 32 patients diagnosed with TNBC was isolated and characterized. This population showed important cell plasticity in terms of expression of epithelia/mesenchymal and stemness markers, suggesting the relevance of epithelial to mesenchymal transition (EMT) intermediate phenotypes for efficient tumor dissemination. Importantly, the CTC signature demonstrated prognostic value to predict the patients' outcome and pointed to a relevant role of tissue inhibitor of metalloproteinases 1 (TIMP1) and androgen receptor (AR) for TNBC biology. Furthermore, we also analyzed the usefulness of the AR and TIMP1 blockade to target TNBC proliferation and dissemination using in vitro and in vivo zebra fish and mouse models. Overall, the molecular characterization of CTCs from advanced TNBC patients identifies highly specific biomarkers with potential applicability as noninvasive prognostic markers and reinforced the value of TIMP1 and AR as potential therapeutic targets to tackle the most aggressive breast cancer
Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients
Background Anti-CGRP monoclonal antibodies have shown notable effectiveness and tolerability in migraine patients; however, data on their use in elderly patients is still lacking, as clinical trials have implicit age restrictions and real-world evidence is scarce. In this study, we aimed to describe the safety and effectiveness of erenumab, galcanezumab and fremanezumab in migraine patients over 65 years old in real-life. Methods In this observational real-life study, a retrospective analysis of prospectively collected data from 18 different headache units in Spain was performed. Migraine patients who started treatment with any anti-CGRP monoclonal antibody after the age of 65 years were included. Primary endpoints were reduction in monthly migraine days after 6 months of treatment and the presence of adverse effects. Secondary endpoints were reductions in headache and medication intake frequencies by months 3 and 6, response rates, changes in patient-reported outcomes and reasons for discontinuation. As a subanalysis, reduction in monthly migraine days and proportion of adverse effects were also compared among the three monoclonal antibodies. Results A total of 162 patients were included, median age 68 years (range 65-87), 74.1% women. 42% had dyslipidaemia, 40.3% hypertension, 8% diabetes, and 6.2% previous cardiovascular ischaemic disease. The reduction in monthly migraine days at month 6 was 10.17.3 days. A total of 25.3% of patients presented adverse effects, all of them mild, with only two cases of blood pressure increase. Headache and medication intake frequencies were significantly reduced, and patient-reported outcomes were improved. The proportions of responders were 68%, 57%, 33% and 9% for reductions in monthly migraine days >= 30%,>= 50%,>= 75% and 100%, respectively. A total of 72.8% of patients continued with the treatment after 6 months. The reduction in migraine days was similar for the different anti-CGRP treatments, but fewer adverse effects were detected with fremanezumab (7.7%). Conclusions Anti-CGRP mAbs are safe and effective treatments in migraine patients over 65 years old in real-life clinical practice
Regulator of calcineurin 1 mediates pathological vascular wall remodeling
Angiotensin-II–driven calcineurin activation and regulator of calcineurin-1 (Rcan-1) expression is required for pathological vascular remodeling in mice
El pensamiento reflexivo a través de las metodologías narrativas: experiencias de innovación en educación superior
Coordinació: Marta Sabariego PuigEste cuaderno es fruto de dos proyectos concedidos en las convocatorias de ayudas a la investigación en docencia universitaria (REDI- CE14-1511 y REDICE16-1660). Están centrados en el estudio de las metodologías de carácter narrativo y (auto)biográfico (Suárez, 2011) sobre el pensamiento reflexivo para el desarrollo personal y profesional del alumnado universitario. Ambos proyectos han permitido la consolidación de una comunidad de práctica, una red interuniversitaria e interdisciplinar de profesorado docente e investigador que tiene como finalidad profundizar en la base teórica, la sistematización y la validación de las experiencias de innovación para el fomento del pensamiento reflexivo a través de las metodologías narrativas. El cuaderno es el producto del análisis colectivo de las experiencias desarrolladas y los resultados obtenidos, vinculando la investigación con la innovación para una docencia de calidad que nos lleve a pensar sobre el valor de una de las vías más importantes para construir y reconstruir significados en las actividades de enseñanza y aprendizaje que se plantean en el espacio universitario: la reflexión.
El texto está organizado en dos secciones. La primera recoge tres apartados teóricos sobre la fundamentación conceptual del pensamiento reflexivo, las características de los espacios de aprendizaje favorables al desarrollo de esta competencia básica para el aprendizaje en la Universidad y el valor de los dispositivos narrativos diseñados. La segunda sección engloba diez experiencias innovadoras que ilustran el desarrollo de un aprendizaje más reflexivo en el alumnado vía escritura narrativa. Finalmente, el cuaderno concluye con propuestas para contribuir a la renovación y validación de una actividad docente organizada y estructurada a este efecto en la educación superio
FULL Investiga Enero a Junio 2020 Número 1
Contiene: A propósito del coronavirus: pandemia o acontecimiento / Carol Fernandez Jaimes -- Desarrollo de nuevos materiales en el contexto de la IV Revolución Industrial y sus efectos en el COVID-19 / Jesús Manuel Gutiérrez Bernal -- El virus que coronó la vulnerabilidad de la formación remota en la educación Chilena y Colombiana” / Marcelo Palominos Bastias,
Lupe García Cano y Víctor Martínez Gutiérrez -- Intuiciones psicosociales sobre la pandemia en el Siglo XXI / Rocío Venegas Luque -- Pensar la economía en tiempos de crisis / Oscar Esteban Morillo Martínez -- Acercamiento al concepto de educación superior en el marco normativo de la educación inclusiva en Colombia / Jose Escobar Romero -- Educación para la paz y la resiliencia en infancias vulneradas, fase II / Ana Dolores Gómez Romero -- Fútbol, de la mediatización global al lavado deportivo / Luis Francisco Buitrago -- Antea, proyecto de investigación que pone en reto a la comunicación como escenario para la transformación ambiental / Janneth Arley Palacios Chavarro -- Del desarrollo económico al desarrollo sos- tenible y el papel de la educación ambiental / Gloria Castaño-Camacho y Rosa Eugenia Reyes Gil -- Investigación en el ámbito turístico y gastronómico / Jesús Alexis Barón Chivara y Sandra Patricia Cote Daza -- Mercado de trabajo y empleabilidad de los profesionales en Colombia / Orlando Salinas Gómez -- El rol de la investigación contable en la academia y la sociedad / Paula Andrea Navarro Pérez -- Hacia la formación competitiva y de desarrollo empresarial / Melva Inés Gómez Caicedo y Diana Geraldine Jiménez García -- El comercio internacional como motor del crecimiento económico / José Vidal Castaño Ramírez -- Hacia el concepto transformacional de la educación superior inclusiva en el contexto colombiano / Castelblanco Daniela, Coronado Laura, Jiménez Wendy, Ocampo Yessica, Pachón Jose, Reyes María, Sánchez Vanesa -- La Inteligencia Artificial como quehacer investigativo y de formación al servicio de la humanidad en el seno del Semillero SofIA / Lucy Nohemy Medina Velandia -- “Un nuevo mundo”. Historieta ilustrada sobre el COVID-19 -- Camilo Rojas Zapata.Fundación Universitaria los Libertadore
The evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients
Background: Mortality due to COVID-19 is high, especially in patients requiring mechanical ventilation. The purpose of the study is to investigate associations between mortality and variables measured during the first three days of mechanical ventilation in patients with COVID-19 intubated at ICU admission. Methods: Multicenter, observational, cohort study includes consecutive patients with COVID-19 admitted to 44 Spanish ICUs between February 25 and July 31, 2020, who required intubation at ICU admission and mechanical ventilation for more than three days. We collected demographic and clinical data prior to admission; information about clinical evolution at days 1 and 3 of mechanical ventilation; and outcomes. Results: Of the 2,095 patients with COVID-19 admitted to the ICU, 1,118 (53.3%) were intubated at day 1 and remained under mechanical ventilation at day three. From days 1 to 3, PaO2/FiO2 increased from 115.6 [80.0-171.2] to 180.0 [135.4-227.9] mmHg and the ventilatory ratio from 1.73 [1.33-2.25] to 1.96 [1.61-2.40]. In-hospital mortality was 38.7%. A higher increase between ICU admission and day 3 in the ventilatory ratio (OR 1.04 [CI 1.01-1.07], p = 0.030) and creatinine levels (OR 1.05 [CI 1.01-1.09], p = 0.005) and a lower increase in platelet counts (OR 0.96 [CI 0.93-1.00], p = 0.037) were independently associated with a higher risk of death. No association between mortality and the PaO2/FiO2 variation was observed (OR 0.99 [CI 0.95 to 1.02], p = 0.47). Conclusions: Higher ventilatory ratio and its increase at day 3 is associated with mortality in patients with COVID-19 receiving mechanical ventilation at ICU admission. No association was found in the PaO2/FiO2 variation
Clustering COVID-19 ARDS patients through the first days of ICU admission. An analysis of the CIBERESUCICOVID Cohort
Background Acute respiratory distress syndrome (ARDS) can be classified into sub-phenotypes according to different inflammatory/clinical status. Prognostic enrichment was achieved by grouping patients into hypoinflammatory or hyperinflammatory sub-phenotypes, even though the time of analysis may change the classification according to treatment response or disease evolution. We aimed to evaluate when patients can be clustered in more than 1 group, and how they may change the clustering of patients using data of baseline or day 3, and the prognosis of patients according to their evolution by changing or not the cluster.Methods Multicenter, observational prospective, and retrospective study of patients admitted due to ARDS related to COVID-19 infection in Spain. Patients were grouped according to a clustering mixed-type data algorithm (k-prototypes) using continuous and categorical readily available variables at baseline and day 3.Results Of 6205 patients, 3743 (60%) were included in the study. According to silhouette analysis, patients were grouped in two clusters. At baseline, 1402 (37%) patients were included in cluster 1 and 2341(63%) in cluster 2. On day 3, 1557(42%) patients were included in cluster 1 and 2086 (57%) in cluster 2. The patients included in cluster 2 were older and more frequently hypertensive and had a higher prevalence of shock, organ dysfunction, inflammatory biomarkers, and worst respiratory indexes at both time points. The 90-day mortality was higher in cluster 2 at both clustering processes (43.8% [n = 1025] versus 27.3% [n = 383] at baseline, and 49% [n = 1023] versus 20.6% [n = 321] on day 3). Four hundred and fifty-eight (33%) patients clustered in the first group were clustered in the second group on day 3. In contrast, 638 (27%) patients clustered in the second group were clustered in the first group on day 3.Conclusions During the first days, patients can be clustered into two groups and the process of clustering patients may change as they continue to evolve. This means that despite a vast majority of patients remaining in the same cluster, a minority reaching 33% of patients analyzed may be re-categorized into different clusters based on their progress. Such changes can significantly impact their prognosis
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Background:
Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke.
Methods:
We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515.
Findings:
Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group.
Interpretation:
In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes.
Funding:
GlaxoSmithKline
Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study
Funder: European Society of Intensive Care Medicine; doi: http://dx.doi.org/10.13039/501100013347Funder: Flemish Society for Critical Care NursesAbstract: Purpose: Intensive care unit (ICU) patients are particularly susceptible to developing pressure injuries. Epidemiologic data is however unavailable. We aimed to provide an international picture of the extent of pressure injuries and factors associated with ICU-acquired pressure injuries in adult ICU patients. Methods: International 1-day point-prevalence study; follow-up for outcome assessment until hospital discharge (maximum 12 weeks). Factors associated with ICU-acquired pressure injury and hospital mortality were assessed by generalised linear mixed-effects regression analysis. Results: Data from 13,254 patients in 1117 ICUs (90 countries) revealed 6747 pressure injuries; 3997 (59.2%) were ICU-acquired. Overall prevalence was 26.6% (95% confidence interval [CI] 25.9–27.3). ICU-acquired prevalence was 16.2% (95% CI 15.6–16.8). Sacrum (37%) and heels (19.5%) were most affected. Factors independently associated with ICU-acquired pressure injuries were older age, male sex, being underweight, emergency surgery, higher Simplified Acute Physiology Score II, Braden score 3 days, comorbidities (chronic obstructive pulmonary disease, immunodeficiency), organ support (renal replacement, mechanical ventilation on ICU admission), and being in a low or lower-middle income-economy. Gradually increasing associations with mortality were identified for increasing severity of pressure injury: stage I (odds ratio [OR] 1.5; 95% CI 1.2–1.8), stage II (OR 1.6; 95% CI 1.4–1.9), and stage III or worse (OR 2.8; 95% CI 2.3–3.3). Conclusion: Pressure injuries are common in adult ICU patients. ICU-acquired pressure injuries are associated with mainly intrinsic factors and mortality. Optimal care standards, increased awareness, appropriate resource allocation, and further research into optimal prevention are pivotal to tackle this important patient safety threat